ScopusElsevier Scopus
Status
Active
Coverage
2005–2026
Source type
Journal
Open access
No
CiteScore
2.3
Best quartile
Q3 · 42nd pctile
| Subject area | Rank | Pctile | Q |
|---|---|---|---|
| Radiology, Nuclear Medicine and Imaging | 209 / 361 | 42nd | Q3 |
| Oncology | 285 / 428 | 33rd | Q3 |
Journal of Cancer Research and Therapeutics
ISSN 0973-1482 · 1998-4138
Publisher: Wolters Kluwer Medknow Publications
Scopus · Q3WoS · SCIE
Is Journal of Cancer Research and Therapeutics indexed in Scopus? Yes — actively indexed in Scopus, coverage 2005–2026, best quartile Q3, CiteScore 2.3.
Is Journal of Cancer Research and Therapeutics in Web of Science? Yes — indexed in the Science Citation Index Expanded.
Is Journal of Cancer Research and Therapeutics open access? No — it is not registered as an open-access journal in DOAJ or Scopus.
2.3
CiteScore 2025
Scopus
Q3
Best quartile
42nd percentile
2
Indexed in
major indexes
Web of ScienceClarivate (SCIE/SSCI/AHCI/ESCI)
ABDCAustralian Business Deans Council 2025
Not listed in ABDC.
DOAJDirectory of Open Access Journals (live)
Checking DOAJ…
FT50Financial Times research list
Not listed in FT50.
UT DallasUTD top-100 business research
Not listed in UT Dallas.
ONOS · APC coveredOne Nation One Subscription (Govt of India)
Not in the ONOS APC-supported list.
Publishing in this journal is not centrally APC-funded under One Nation One Subscription.
Official sources & links
Related journals
- Journal of Cardiovascular Echography
- Journal of Clinical Ophthalmology and Research
- Journal of Conservative Dentistry and Endodontics
- Journal of Craniovertebral Junction and Spine
- Journal of Current Ophthalmology
- Journal of Cytology
- Journal of Datta Meghe Institute of Medical Sciences University
- Journal of Diabetology
Explore this journal in the interactive dashboard →
Index data is curated from public sources (Scopus, Web of Science, ABDC, FT50, UT Dallas, DOAJ). CiteScore and quartiles reflect the latest available Scopus release. Always verify a journal's current status on its official source before submitting.